A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules

ConditionProgression
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-85
SponsorShanghai Zhongshan Hospital

About this trial

A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules

Eligibility criteria

Qualifiers

Aged between 18 and 85 years;

GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);

The maximum diameter of the GGO is bigger than 8mm and smaller than 3cm;

For single GGO: obvious progress was observed in pure GGO or the solid component of mixed ground glass nodules was more than or equal to 2 mm

Disqualifiers

Patients who participated in any drug and / or medical device clinical trials within one month before the trial

had severe disease conditions

allergy to narcotic drugs

had other autoimmune disease

Trial design

Treatments tested in this trial

  • Ablation therapy

Treatment groups

120 Participants
are divided into 1 treatment group

Sponsors and collaborators